Jim Sullivan

Jim Sullivan, Ph.D., is a Venture Partner with Orbimed. Prior to joining Orbimed, Dr. Sullivan was a Vice President of Research at Abbvie. In this role, he was responsible for AbbVie’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Jim has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. These include recently launched combination products for HCV (Mavyret and Viekira), the-first-in- class Bcl2 selective inhibitor, Venclexta and multiple compounds currently in Phase II or III trials. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Jim is an adjunct faculty member at Northwestern University and serves on the board of a number of companies and foundations. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College in Dublin, Ireland, and conducted post-doctoral research in neurobiology at Northwestern University.